TIMI study
Jump to navigation
Jump to search
Introduction
857 patients, with unstable angina or NSTEMI
Groups: (treatment prior to PCI)
- eptifibatide plus unfractionated heparin or enoxaparin vs
- bivalirudin monotherapy
both groups received pretreatment aspirin & clopidogrel just prior to PCI
Results:
- outcome nonsignificantly favoring eptifibatide
- shorter duration of ischemic events with eptifibatide
- bleeding less common with bivalirudin
More general terms
Additional terms
References
- ↑ Gibson CM et al, A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and thrombotic agents: The PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006. 47:2364 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16781360
Bittle JA, The future of an illusion. J Am Coll Cardiol 2006. 47:2380 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16781362